Tag Archives: PRGN-3006

JPM 2024 Analysis Days 2 & 3: Imugene, CRISPR Tx, and Precigen

On the second and third days of JPM 2024, Celltelligence covered presentations by Imugene (webcast / presentation), CRISPR Tx (press release / webcast), and Precigen (webcast / presentation). Below, Celltelligence provides insights and context for each presentation. The following topics are covered: 

About The Author

The Celltelligence Team

|
Content Leads & Contributors

The Celltelligence team has combined experience in oncology, including cell therapy, CAR-T, immunology, microbiology, biochemistry, and other various fields in life sciences. Our team members include PhDs, industry veterans, and analysts tuned to The Street – all of whom help to create a more actionable service of delivering cell therapy intelligence.

If you receive our email blasts, you already have an account.

Sign UpFREE

You’ll be able to access the full article from your Celltelligence Library after signing up.

JPM 2023 Analysis Day 3: Century Tx, Atara Bio, and Precigen

On the third day of the JPM 2023, Celltelligence covered presentations by Century Tx (press release / webcast / presentation), Atara Bio (webcast / presentation), and Precigen (press release / presentation). Below, Celltelligence provides insights and context for each presentation. The following topics are covered below.

About The Author

The Celltelligence Team

|
Content Leads & Contributors

The Celltelligence team has combined experience in oncology, including cell therapy, CAR-T, immunology, microbiology, biochemistry, and other various fields in life sciences. Our team members include PhDs, industry veterans, and analysts tuned to The Street – all of whom help to create a more actionable service of delivering cell therapy intelligence.

If you receive our email blasts, you already have an account.

Sign UpFREE

You’ll be able to access the full article from your Celltelligence Library after signing up.

Clinical Results from Autolus, Cellectis, and Precigen; ASH 2022 Analysis 7

ASH 2022 Analysis 7: Autolus, Cellectis, and Precigen presented updated data in ALL, PTCL, and AML. Below, Celltelligence provides insights and context for key selected presentations. The following topics are covered below: 

About The Author

The Celltelligence Team

|
Content Leads & Contributors

The Celltelligence team has combined experience in oncology, including cell therapy, CAR-T, immunology, microbiology, biochemistry, and other various fields in life sciences. Our team members include PhDs, industry veterans, and analysts tuned to The Street – all of whom help to create a more actionable service of delivering cell therapy intelligence.

If you receive our email blasts, you already have an account.

Sign UpFREE

You’ll be able to access the full article from your Celltelligence Library after signing up.